

Welcome to the session AI and Cancer: Unleashing Opportunities, Overcoming Challenges

Clustering event powered by INCISIVE and the AI4HI cluster









Success stories of cancer medical imaging in advancing cancer research and patient care









Success stories of cancer medical imaging in advancing cancer research and patient care



Mr. Vladan Zdravković Project manager at Visaris INCISIVE project



Mr. Javier Sánchez Clinical Science Lead South Europe at Philips



Mr. Mario Aznar CEO of Matical Innovation PRIMAGE and CHAIMELEON projects



Mr. Pau López Head of the Informations Systems Technical Office of the Catalan Institute of Health (ICS)



Mr. Javier Miguel Aquerreta Biomedical Engineer at La Fe Health Research Institute



Mrs. Susanna Aussó Head of AI at TIC Salut Social Foundation, INCISIVE project



ACISIVE HICISIVE HEUCAIM



Mr. Vladan Zdravković Project manager at Visaris INCISIVE project



INCISIVE. The challenge

Early cancer detection could identify tumors at a time when outcomes are superior, and treatment is less aggressive

But there are number of problems and challenges. Three main questions are as follows:

- how to convince medical professionals to use AI tools
- how to improve precision
- how to back up results with histopathology data



These projects has received funding from the European Union's Horizon 2020 research and innovation programme



ÎNCISIVE EUCAIM



INCISIVE. The impact

Al as assistive technology saving time In initial tests Visaris proved that with AI software users are saving time for:

- automatic image orientation experienced radiologist up to a minute and inexperienced up to two minutes per patient
- positioning experienced radiologist up to two minutes and inexperienced up to five minutes
- enlargement and focus experienced radiologist up to five minutes and inexperienced up to ten minutes

In initial tests Revive proved that with AI software users are saving for:

- automatic reporting experienced doctor up to four minutes and inexperienced doctor up to six minutes per patient search for symptoms and diagnoses - experienced doctor up to ten minutes and inexperienced doctor up to two hours cancer detection (95%) precision (for melanoma and skin cancer) - experienced doctor up to five minutes and inexperienced doctor up to ten minutes (inexperienced doctors have precision between 60% and 75% depending on cancer type)





These projects has received funding from the European Union's Horizon 2020 research and innovation programme



INCISIVE. The challenge

Three main tasks for the industry:

- Find better more precise solutions
- Back it with data (histopathology and efficiency tests)
- Educate

At this moment for us is the main task to explain:

- how to choose the right tool for the right purpose
- what are features
- how much users can depend on results



It seems that ai is here to stay but

Focus on Assistive functions Prove time and money savings **Build cases with histopathology** Work with professionals who clearly understand possibilities

> These projects has received funding from the European Union's Horizon 2020 research and innovation programme





RESIVE RESIVE



Mr. Javier Sánchez

"Al for Precision Diagnosis"



Clinical Science Lead South Europe at Philips



Al for Precision Diagnosis





Improve outcome







AI CT Reconstruction

Supervised residual learning to remove noise from images (improve SNR) Advanced low-dose simulation [1] to generate training data



Philips Research Hamburg



Training data pair

acquired full dose

simulated 25% dose





AI CT Reconstruction Example: Abdomen

FBP

Philips Precise Image



AI clinical results demonstrate simulated images at 50% less dose and were reviewed by board-certified radiologists. Results from case studies are not predictive of results in other cases. Results in other cases may vary.



Philips Precise Image (cleaner)





Different k-space sampling









SmartSpeed AI

Delayed HR-3D-mDIXON

Comparison

C-SENSE (previous)



C-SENSE 3.0, 1m46s 0.86/0.86/0.8mm



Courtesy : Kumamoto Chuo Hospital, Japan Ingenia Elition 3.0T X, R11.0

SmartSpeed AI



AI C-SENSE 7.5, 2m2s 0.7/0.7/0.7mm





SmartSpeed AI

Delayed HR-3D-mDIXON

Comparison

SmartSpeed AI



AI C-SENSE 7.0, 2m14s 0.75/0.75/0.75mm



Courtesy : Kumamoto Chuo Hospital, Japan Ingenia Elition 3.0T X, R11.0

SmartSpeed AI



AI C-SENSE 7.0, 3m34s 0.6/0.6/0.6mm





Al for Precision Diagnosis





Improve outcome







Al-Based Lymph Node Assessment Reading Augmentation in Oncology

- Lymph nodes important for TNM staging and follow-up analysis
- Malignant if short axis diameter > 10 mm (RECIST)
- Lymph nodes are numerous, vary in size and shape, have low contrast
- Manual assessment often limited to selected LNs
- Opportunity: Automated detection, segmentation & labelling could significantly improve daily oncological reading















Al-Based Lymph Node Assessment Results



[5] *A.-I. luga et al.,* "Automated mapping and N-Staging of thoracic lymph nodes in contrast-enhanced CT scans of the chest using a fully convolutional neural network", European Journal of Radiology, 2021

[6] M. Rinneburger et al., "Automated Detection and Segmentation of Cervical Lymph Nodes in CT using 3D Foveal Fully Convolutional Neural Networks", European Radiology Experimental, submitted

Philips Research Hamburg







[4] *A.-I. luga et al.,* "Automated detection and segmentation of thoracic lymph nodes from CT using 3D foveal fully convolutional neural networks", *BMC Medical Imaging,*





RESIVE RESIVE EEUCAIM



Mr. Mario Aznar CEO of Matical Innovation PRIMAGE and CHAIMELEON projects



The challenge



RIMAGE

PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers

Area of application: Neuroblastoma & Diffuse Intrinsic Pontine Glioma

NB: most frequent solid cancer of early childhood (7% childhood malignancies). Staging and diagnosys is made using Cross-sectional imaging (CT or MRI), MIBG imaging agent scan, and bone marrow biopsy to deliver a pre-surgical risk stratification. Progress to enable earlier detection of neuroblastoma in high risk patients is very much needed, as the age at diagnosis has proven to be a crucial factor in the NB prognosis

DIPG: is the leading cause of brain tumour-related death in children. Due to the position of DIPGs deep in the brain and close to vital structures DIPG, biopsy is not an available option. DIPG is diagnosed using MRI or CT scan.

Imaging plays a very important role in the diagnosis, staging, treatment planning, response evaluation and in follow-up of these diseases, as well other related data. In-silico technologies could help provide better diagnosis and prediction of treatment response. I.e: avoiding invasive techniques (Virtual biopsy); simulating tomour growth and predicting biomarkers progression for better clinical decisions making.

DATA IS ALL: NO DATA = NO GAME



These projects has received funding from the European Union's Horizon 2020 research and innovation programme





The solution



PRIMAGE

Medical imaging Artificial intelligence ood cancer research

Data: Imaging and Related

Biomarkers

In-silico modelling of Solid Tumors

therapies follow-up





These projects has received funding from the European Union's Horizon 2020 research and innovation programme



ÎNCISIVE EUCAIM



The impact



PRIMAGE

Medical imaging Artificial intelligence Childhood cancer research

MOST PROMISING RESULTS IDENTIFIED

Computing Platform Specification Extended Model Execution Environment (MEE) Computing Platform Specification Medexprim Suite™ (Radiomics Enabler® solution) for

automated image extraction and deidentification tool

Methodology for Clinical data mapping Image quality control tool

Radiomics models for NB and DIPG

Image registration methodology using rigid and non-rigid approaches for NB and DIPG, including the automatic selection of best registration algorithm with quantitative metrics (SW/tool)

Image enhancement (signal normalization, denoising) methodology for NB and DIPG (SW/tool)

Generation of manual segmentation data set from MRI patient data for NB and DIPG (set of data)

MR automatic segmentation models for NB and DIPG (model/tool)

Deep transfer learning and radiomics feature prediction of survival of patients with NB and DIPG (SW/tool)

A novel methodology of quantitative diffusion: a use-case to classify neuroblastic tumours (SW/tool)

Selection and visualization of features using unsupervised learning (SW/tool)

Multiscale modelling of tumour growth and progression

Market maturity: Market Ready Market creation potential: High Project: PRIMAGE Innovation Topic: Health & Care

9 INDUSTRY, INNOVATION AND INFRASTRUCTURE

Market maturity: Market Ready Market creation potential: High Project: PRIMAGE Innovation Topic: Health & Care

21





Computational tools for the processing and analysis of imaging data

Market maturity: Tech Ready Market creation potential: Minor Project PRIMAGE Innovation Topic: Health & Care

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA 9 - SPAIN UNIVERSITA DI PISA - ITALY

9 IND DERASTRUCTURE

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA -ITALY CHEMOTARGETS S.L. - SPAIN UNIVERSIDAD DE ZARAGOZA - SPAIN

Platform for the collection, exploration and analysis of clinical data

9 MOUSTRY, INNOVATION AND INFRASTRUCTURE

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA 9 - SPAIN QUIBIM SOCIEDAD LIMITADA 9 - SPAIN MEDEXPRIM ~ FRANCE



European Society for Paediatric Oncology (SIOPE) uptaking PRIMAGE Platform as their Imaging Management Tool





ACISIVE INCISIVE EUCAIM



Mr. Pau López Head of the Informations Systems Technical Office of the Catalan Institute of Health (ICS)





DigiPatICS project

Incorporate Digital Pathology and Artificial Intelligence in Pathology Departments, with an organizational change that modifies work dynamics, responds to current and future challenges, and improves quality, efficiency, effectiveness, equity, speed, systematicity, and reproducibility of diagnoses, affecting other disciplines and increasing patient safety







The solution

- Deployment of 24 scanners
- Redesign pathologist process
- Create a new LIS
- Incorporation of UPC University to develop IA algorithms
- Creation of an IA platform and a visualization framework
- Involve ICS pathologies to define their algorithms
- Deploy new IT services and infrastructures
- Development of a new platform to storage the slides -> PAT-SIMDCAT















Salut/Institut Català de la Salut

The impact

- Networking between the 8 ICS hospital centers (168 pathologist) with telediagnosis, case sharing and teaching, increasing patient safety, reproducibility, and fairness in diagnosis
- Standardized DICOM integration of images in SIMDCAT with more than 1,5 Millions images digitalized in SIMDCAT (1,5 PB), Since November 2021
- 4 algorithms of breast cancer developed and deployed in the slide viewer (Ki67, Her2, RP, RE)
- Developing new algorithms in lung cancer and cancer detection in HE
- Preparing new IA developments









alà de la Salut

RESIVE RESIVE EUCAIM



Mr. Javier Miguel Aquerreta

Biomedical Engineer at La Fe Health Research Institute



The challenge

Interoperability between centres: Building a DataWarehouse with a CDM.









The solution











The impact

• Integration between clinical data and imaging data.

Allow more complex data analysis



• Use of CDM: easier interoperability between centres









